Clinical guideline writers often conflicted

February 2011
CMAJ: Canadian Medical Association Journal;2/22/2011, Vol. 183 Issue 3, pE139
Academic Journal
The article focuses on the conflict of interests of clinical guidance writers to clinical practice guidelines. Niteesh Choudhry, assistant professor at Harvard Medical School in Boston, Massachusetts mentions that a close examination indicates high rate of interaction between guideline writers and pharmaceutical companies. Choudhry adds the need to have an approach that determines the permissible relationship of guideline writers and pharmaceutical companies.


Related Articles

  • Study: Referral process needs standardizations, new protocols.  // Medical Economics;12/25/2014, Vol. 91 Issue 24, p16 

    This article discusses a study on U.S. patient referral process, referencing a research by Niteesh K. Choudhry and Joshua M. Liao, both of Brigham and Women's Hospital and Harvard Medical School in Boston, and Allan S. Detsky of the University of Toronto, Mount Sinai Hospital and University...

  • Free Post-MI Medications Improve Adherence Without Added Costs. Vinall, Maria // MD Conference Express;Dec2011, p17 

    The article focuses on the post-myocardial infarction free Rx event and economic evaluation (MI FREEE) trial conducted by doctor Niteesh K. Choudhry of Harvard Medical School in Boston, Massachusetts. The cluster-randomized, controlled policy study improve treatment adherence without increasing...

  • Conflicts of Interest: Bias or Boon? Tomaszewski, Christian // Journal of Medical Toxicology;Jun2006, Vol. 2 Issue 2, p1 

    Offers observation on the conflict of interest issue in the field of medical research. Factor that influence the integrity of science; Extent of the pharmaceutical industry's financial influence in biomedical research; Key predictor for a result favorable toward the product being studied.

  • In Defense of Industry-Physician Relationships. NAKAYAMA, DON K. // American Surgeon;Sep2010, Vol. 76 Issue 9, p987 

    The objective was to examine the economic, ethical, and legal foundations for conflict of interest restrictions between physicians and pharmaceutical and medical device industries ("industry"). Recently academic medical centers and professional organizations have adopted policies that restrict...

  • Fighting about conflict of interest: where should the balance lie? Misselbrook, David // British Journal of General Practice;Feb2016, Vol. 66 Issue 643, p66 

    The article focuses on the conflict of interest (COI) management in medicine and pharmaceutical industry. Topics mentioned include the promotional money used by physicians, the protection against COI, and the drug industry management. Also mentioned are the financial gain in the pharmaceutical...

  • Harvard Medical School Revises, Clarifies, Strengthens Its Conflict of Interest Policy.  // Ascribe Newswire: Medicine;6/10/2004, p26 

    Harvard Medical School's policy is generally considered to provide strong safeguards about conflicts of interest in the relationships between faculty and the for-profit industry. The initial review was conducted by two committees, one looking at clinical research headed by Barbara McNeil,...

  • Paying for the view. Iheanacho, Ike // BMJ: British Medical Journal (International Edition);1/19/2008, Vol. 336 Issue 7636, p160 

    This article argues that it is time to deal with the conflicts of interest that taint the view of medical opinion leaders who are in the pocket of pharmaceutical companies and/or special interest groups. The author says doctors should wear their sponsorships on their clothes like race car...

  • Lines Disintegrating Between Industry, Academic Research. Benowitz, Steve // JNCI: Journal of the National Cancer Institute;09/06/2000, Vol. 92 Issue 17, p1377 

    Reports on the growing potential for conflicts of interest among academic scientists funded by the pharmaceutical industry. Importance of industry-academe collaboration; Establishment of contractual arrangements to prevent potential conflicts.

  • Conflicted Interest. Comer, Ben // Pharmaceutical Executive;Apr2013, Vol. 33 Issue 4, p82 

    The article presents the author's comments on the influence of pharmaceutical companies' payment for services on the physicians' art of medicine. The author mentions ProPublica's Dollars for Docs project, which is meant to aggregate and freely disseminate all available data on the payments...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics